EMA Begins Review of Pfizer and Valneva’s Lyme Disease Vaccine, a Potential First

Europe’s medicines regulator has taken the first formal step toward what could be the first approved human vaccine against Lyme disease in decades.

The European Medicines Agency has validated the marketing authorisation application for the Lyme vaccine candidate developed by Pfizer and Valneva. Pfizer holds exclusive rights to manufacture and commercialise it.

What validation means

Validation is procedural rather than substantive: the agency confirms the application is complete enough to assess and starts the formal review clock.

It is not an assessment of whether the vaccine works, and it is a meaningful milestone in that it confirms the dossier — manufacturing, quality, preclinical and clinical data — is assembled to the standard required. Applications are occasionally refused at this stage.

How the vaccine works

It is a six-valent protein subunit vaccine based on outer surface protein A (OspA), targeting six Borrelia OspA serotypes found across North America and Europe.

The mechanism is unusual and rather elegant. OspA is expressed by Borrelia bacteria while they are in the tick’s gut, and downregulated once they migrate into a mammalian host.

So the vaccine does not primarily work inside the vaccinated person. Antibodies in blood taken up by a feeding tick reach the bacteria in the tick’s gut and neutralise them there — interrupting transmission before infection is established, rather than fighting an infection already underway.

Six serotypes are needed because OspA varies between Borrelia species, and the species causing Lyme disease differ between North America and Europe. A vaccine covering only the North American variant would be useless across most of Europe.

The trial

The application is backed by the Phase 3 VALOR trial, which enrolled 9,437 participants aged 5 and older across the US, Canada and Europe. The vaccine showed more than 70% efficacy in preventing Lyme disease and was well tolerated, with no new safety concerns.

Recruiting across three continents is necessary rather than ambitious, given the serotype variation — a vaccine claiming coverage of both American and European strains must demonstrate it where those strains circulate.

The history that hangs over this

A Lyme vaccine existed before. An OspA-based product was approved in the United States in the late 1990s and withdrawn from the market in 2002.

It was not withdrawn because it failed. Its efficacy was reasonable, and the withdrawal followed reports of arthritis allegedly linked to vaccination, litigation, negative publicity and collapsing sales. Subsequent investigation did not substantiate the claimed link, and reviews have generally concluded the vaccine was safe.

The episode is frequently cited as a case where a useful vaccine was lost to a safety concern that evidence did not support — and it explains why any new OspA vaccine faces particular scrutiny, and why the “no new safety concerns” language in the trial report carries more weight than usual.

Why a vaccine is wanted

Lyme disease affects over 100,000 people a year in Europe and remains common in parts of North America, and there is no approved human vaccine.

Most cases are treatable with antibiotics when caught early. The difficulty is that early Lyme is easy to miss — the characteristic rash is absent in a meaningful proportion of cases, and initial symptoms are non-specific. Untreated infection can progress to arthritis, neurological involvement and cardiac complications, and a subset of patients report persistent symptoms after treatment that remain contested and poorly understood.

Prevention avoids that entire uncertain territory, which is much of the appeal.

The practical limitations

Two are worth noting. OspA-based protection depends on antibody levels being high when a tick feeds, which implies periodic boosting aligned with tick season rather than lifelong protection from a primary series.

And the vaccine covers Lyme disease specifically. Ticks transmit several other pathogens — including agents causing anaplasmosis, babesiosis and tick-borne encephalitis — against which this offers nothing. Vaccinated people still need to avoid tick bites.

Why tick-borne disease is expanding

The case for a Lyme vaccine has strengthened over recent decades because the disease itself has spread, and the reasons are worth understanding.

Tick populations have expanded in range and abundance across North America and Europe. Warmer winters allow ticks to survive at higher latitudes and altitudes than previously, and lengthening warm seasons extend the period during which they are active and seeking hosts.

Land use matters too. Reforestation across parts of the northeastern United States and Europe, combined with expanding deer populations and suburban development at the woodland edge, has increased contact between humans and tick habitat.

The result is that areas which had little Lyme disease a generation ago now report substantial case numbers, and clinicians in those regions are diagnosing a condition they were not trained to expect. A vaccine addresses a growing exposure rather than a static one — which strengthens both the public health case and the commercial one.

“I look forward to collaborating with the EMA as this vaccine candidate advances through the review cycle,” Pfizer’s chief vaccines officer said. A validation is the start of review, not an approval. Regulatory news, not medical advice.